09:14 AM EDT, 08/21/2025 (MT Newswires) -- (Updates to add Novo Nordisk's ( NVO ) comment in the fourth paragraph)

Novo Nordisk's ( NVO ) weight-loss drug Wegovy is seeing an increased demand in the UK as rival Eli Lilly ( LLY ) plans a significant price hike for its competing treatment, Mounjaro, Bloomberg reported Thursday.

According to the report, pharmacies are warning patients about the upcoming 170% price increase in September and are helping them switch to the more affordable Wegovy.

While Lilly says it is working with health care providers to ensure continued access, Novo Nordisk ( NVO ) is keeping its prices steady, the report said.

Novo Nordisk ( NVO ) told MT Newswires it has no plans to change its offerings in the UK and remains focused on making its medicines innovative, accessible, and affordable for those who need them.

Eli Lilly ( LLY ) did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)